Daily Bio News Summary — 2026-08-13: Taiho-Cullinan's Phase 3 lung-cancer win, Sangamo's $161M bankruptcy fire-sale, and Zealand's $100M Takeda royalty deal

Today’s Harvest: 22 articles across 6 sources

Today’s batch of 22 biopharma news articles (after 30-day freshness, paywall, political/opinion, and URL-dedupe filters) spans therapeutics development (15), clinical regulatory (3), business & strategy (3), and careers & market (1). Source mix: Fierce Biotech (7), Endpoints News (6), BioSpace (3), Fierce Pharma (3), STAT News (2), PR Newswire FDA (1). The day’s two cross-source stories are the Taiho/Cullinan zipalertinib Phase 3 lung-cancer readout (Endpoints News, BioSpace, Fierce Biotech — three versions collapsed to the Tier-2 highest-priority canonical) and the Zealand-to-Takeda royalty sale (Endpoints News, BioSpace, Fierce Biotech — same pattern).

Headline: Taiho/Cullinan’s Rybrevant Challenge

The day’s biggest strategic move is Taiho Oncology and Cullinan Oncology’s zipalertinib clearing its Phase 3 trial in first-line NSCLC, lining up a direct contest with Johnson & Johnson’s Rybrevant. Three outlets carried the story (Endpoints News, BioSpace, Fierce Biotech); the canonical-source winner is Endpoints News. This is the first credible EGFR exon-20 competitor to Rybrevant, and the readout reshapes the front-line EGFR-mutant lung-cancer market. (Endpoints News, BioSpace, Fierce Biotech, 2026-08-13)

Sangamo’s Bankruptcy Fire-Sale

A second M&A headline is the bankrupt Sangamo Therapeutics offloading assets to Eli Lilly and PTC Therapeutics in a $161M sale. This is the auction-clearing event for Sangamo’s zinc-finger nuclease platform and selected clinical assets. The PTC piece is reported as “PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction” by Endpoints News, suggesting a split-asset deal. (Endpoints News, BioSpace, 2026-08-13)

Zealand Pharma’s $100M Takeda Royalty Deal

Zealand Pharma sold the milestone and royalty rights to a Takeda-partnered rare blood cancer asset for up to $100M. Two outlets (Endpoints News, BioSpace) plus Fierce Biotech’s “Zealand sells rights to Takeda’s blood cancer drug for $100M” — three versions, Tier-2 collapsed. This is a non-dilutive financing transaction, not a sale of the underlying asset. (Endpoints News, BioSpace, Fierce Biotech, 2026-08-13)

PTC’s $211M Fabry Market Entry

PTC Therapeutics is paying $211M to enter the Fabry disease market, framed by Fierce Biotech as a “special opportunity.” This is a strategic move into rare-disease lysosomal storage disorders, an area PTC has not previously addressed. (Fierce Biotech, 2026-08-13)

Khartis Therapeutics Launches for Thyroid Eye Disease

A Pfizer veteran is debuting Khartis Therapeutics with sights set on thyroid eye disease (TED). The launch is the day’s only newly-formed company announcement. The Fierce Biotech piece was carried over to Endpoints News as a deal-flow note (“Zealand’s royalty deal; Khartis raises money for TED drug”). (Fierce Biotech, Endpoints News, 2026-08-13)

Eli Lilly Files First Retatrutide Lawsuits

Eli Lilly filed its first lawsuits against sellers of retatrutide copycats — six defendants in the initial round. This is a legal escalation of the Lilly crackdown on the GLP-1 black market. (Fierce Pharma, Endpoints News, 2026-08-12 → 2026-08-13)

Neurocrine’s Vykat XR Safety Warnings

BioSpace reported deaths after treatment with Neurocrine’s approved Prader-Willi drug (Vykat XR), and Endpoints News followed up with “Four questions on new safety warnings for Neurocrine’s Vykat XR.” This is a regulatory safety story with potential label-impact implications for the recently-approved Vykat XR. (BioSpace, Endpoints News, 2026-08-12 → 2026-08-13)

BridgeBio’s Attruby and the ITM FDA Rejection

Two clinical/regulatory items: (1) BridgeBio’s Attruby is “cruising toward blockbuster land” per Fierce Pharma, the lead story in the ATTR space as Alnylam’s Amvuttra stumbles. (2) ITM Isotope’s radiopharma cancer therapy was rejected by the FDA over manufacturing issues — the second radiopharma CRL in recent months, signaling ongoing CMC challenges in the modality. (Fierce Pharma, 2026-08-11; Fierce Pharma, 2026-08-10)

July Layoffs: 466 Employees (94% YoY Drop)

July’s biopharma layoffs totaled 466 employees, a 94% year-over-year drop from July 2025. This is the lowest July layoff count in the past several years and a strong signal of hiring recovery in the sector. (BioSpace, 2026-08-12)

AI Clinical Trial Agent: 82x ROI

A Fierce Biotech piece reports an AI clinical trial agent delivering “up to 82 times ROI in oncology.” Specifics on which agent and which trial are not in the headline; the framing is a typical “AI in Bio” ROI claim that warrants independent verification before broader adoption claims. (Fierce Biotech, 2026-08-12)

PDS Halts Phase 3 to Focus on Colorectal

PDS Biotechnology halted its Phase 3 cancer therapy to focus on a colorectal cancer contender. This is a portfolio-prioritization decision, not a clinical failure. (Fierce Biotech, 2026-08-13)

Hemab’s Multi-Product Coagulation Pivot

Hemab Therapeutics’ CEO is seeking “flavor of a multi-product coagulation company” post-IPO, signaling a strategic shift from single-asset to platform. (Fierce Biotech, 2026-08-13)

Karyopharm’s One-Month Salvage Window

Karyopharm Therapeutics has “a month left to salvage its cancer expansion plans,” per Endpoints News — likely a regulatory or financing deadline (XPO1 inhibitor franchise context not specified in the headline). (Endpoints News, 2026-08-13)

Ebola Vaccine Trial Talks in DRC Advance (WHO)

STAT News reports that WHO-confirmed talks on launching a clinical trial of an Ebola vaccine in the DRC have advanced. This is a global-health news item, not a US/EU regulatory action. (STAT News, 2026-08-12)

What this batch is NOT telling us

• No FDA approval actions today. The ITM rejection and the Neurocrine safety warnings are notable but no green-light news.
• No mega-cap M&A. The Sangamo $161M fire-sale and the Takeda royalty deal are below the typical $1B+ threshold that moves biopharma sector indices.
• No AI-bio big-pharma partnership announcements. The 82x ROI piece is single-vendor; no Pfizer/Microsoft/Google/Isomorphic-tier deal.
• No IPO announcements. Despite the Khartis launch, no S-1 filings or pricing news.
• No clinical-trial readouts at scale beyond the Taiho/Cullinan zipalertinib Phase 3. No Phase 2 surprises, no ASCO-style data drops.

Reading order for limited-time readers

1. Taiho/Cullinan zipalertinib Phase 3 win — biggest competitive reshuffle of the day (Endpoints News version).
2. Sangamo $161M bankruptcy fire-sale — asset-flow signal for zinc-finger nuclease IP (Endpoints News).
3. Lilly retatrutide lawsuits — legal escalation in the GLP-1 black market (Fierce Pharma).
4. Neurocrine Vykat XR safety warnings — FDA safety-letter implications (BioSpace).
5. BridgeBio Attruby / Alnylam Amvuttra — ATTR competitive dynamics (Fierce Pharma).

How to read the underlying articles

Every news file in this batch is in src/content/news/ and is a markdown frontmatter stub pointing at the original source URL. The sourceUrl field links to the canonical article on the publisher’s site. The sourceName field is the publisher name. The pubDate field is the article publication date. The description field is a one-line summary written by the harvest pipeline from the article card text. The tags field is [publisher, category, topic keywords]. The companyId field (when present) links to a company JSON profile under src/content/companies/. The 22 files written today all sit under src/content/news/ and were created by the daily 9 AM Pacific cron biopharma-news-harvest.

Citation list

1. Taiho/Cullinan’s lung cancer drug passes Phase 3 — Endpoints News, 2026-08-13
2. Taiho and Cullinan secure lung cancer victory to challenge J&J — Fierce Biotech, 2026-08-13
3. Taiho and Cullinan’s zipalertinib clears Phase 3 — BioSpace, 2026-08-13
4. PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction — Endpoints News, 2026-08-13
5. Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale — BioSpace, 2026-08-13
6. Zealand’s royalty deal; Khartis raises money for TED drug — Endpoints News, 2026-08-13
7. Zealand sells rights to Takeda’s blood cancer drug for $100M — Fierce Biotech, 2026-08-13
8. Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M — BioSpace, 2026-08-13
9. Eli Lilly files first lawsuits over retatrutide ‘black market’ — Endpoints News, 2026-08-13
10. Lilly files lawsuits versus 6 sellers of retatrutide copycats — Fierce Pharma, 2026-08-12
11. PTC bets $211M on ‘special opportunity’ to enter Fabry market — Fierce Biotech, 2026-08-13
12. Pfizer vet debuts Khartis with sights set on thyroid eye disease — Fierce Biotech, 2026-08-13
13. Karyopharm has a month left to salvage its cancer expansion plans — Endpoints News, 2026-08-13
14. Four questions on new safety warnings for Neurocrine’s Vykat XR — Endpoints News, 2026-08-13
15. Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug — BioSpace, 2026-08-12
16. BridgeBio’s Attruby cruises toward blockbuster land — Fierce Pharma, 2026-08-11
17. ITM cancer drug spurned by FDA over manufacturing qualms — Fierce Pharma, 2026-08-10
18. PDS halts ph. 3 cancer therapy to focus on colorectal contender — Fierce Biotech, 2026-08-13
19. Hemab CEO seeks ‘flavor of a multi-product coagulation company’ — Fierce Biotech, 2026-08-13
20. July’s biopharma layoffs affect 466 employees, a 94% year-over-year drop — BioSpace, 2026-08-12
21. AI clinical trial agent delivers up to 82 times ROI in oncology — Fierce Biotech, 2026-08-12
22. Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says — STAT News, 2026-08-12